Crescendo Biologics

Please note: The information displayed on this page might be outdated.
Crescendo Biologics: Crescendo Biologics is a clinical stage company developing T cell enhancing therapeutics.

Crescendo’s lead programme, CB307, is a CD137 (4-1BB) x PSMA bispecific. CB307’s unique format delivers tumour-specific killing, while avoiding systemic toxicity, and can be applied to a broad range of PSMA-positive cancer indications. It is designed to cause the proliferation of tumour-specific T cells, creating a safe, broad, longer-lasting anti-tumour response and will be in the clinic in early 2021.

Behind the lead programme there is a pipeline of innovative, first or best-in-class T cell enhancing molecules in development. This pipeline is underpinned by Crescendo's novel, patent-protected Humabody® VH platform, which generates fully human VH domains (Humabodies). Humabodies are robust and stable molecules and can be easily assembled into multi-specific formats which can access novel biology. Humabodies can also deliver significantly improved tumour accumulation and penetration compared to conventional monoclonal antibody-based approaches. Crescendo's Humabody platform has received third party validation through Crescendo’s clinical and pre-clinical collaborations. Crescendo has a multi-target collaboration in immuno-oncology, ADCs and CAR-Ts with Takeda, worth up to $790M, and has licensed an innovative programme for an inflammatory target to Zai Lab. Crescendo has also recently signed a clinical development partnership deal with Cancer Research UK for its PD1-LAG3 programme. Crescendo’s innovative, topical therapy CB001, (ZL-1102), for inflammatory indications including psoriasis, was licensed to Zai Lab in 2018 and is currently under evaluation in a phase 1 clinical trial (Trial ID: ACTRN12620000700932).

Crescendo would be delighted to talk to investors about its plans for future growth.
Biotech Company / Healthcare/Biotechnology
Based in...
Europe, United Kingdom
Clinical Stage
Phase l or ll
Disease Space
Immuno-Oncology, Immunotherapy, Oncology
Market Cap
100MM - 500MM
Therapeutic Modalities
Antibodies, Platform Technology
Meditrina Building 260
Babraham Research Campus
Cambridge, Cambridgeshire CB223AT
United Kingdom

Company Participants at Spring Private Company Showcase

Theodora Harold
Crescendo Biologics, CEO
Theodora Harold was appointed CEO of Crescendo Biologics (Crescendo) in May 2019. She joined the Company in 2016 and was promoted to CEO, having previously held both CFO and CBO roles. She has over 20 years’ experience with both private and listed biotech SMEs and to date she has helped raise c.$200m for the sector. She was on the founding teams of both MISSION Therapeutics and PsiOxus Therapeutics where she was CFO, as well as having held executive roles with companies such as Cytomyx Holdings Plc and Orthomimetics. Theodora qualified as Chartered Accountant with PricewaterhouseCoopers and read Classics at Trinity College, Cambridge.